A combination of berberine and gamma-oryzanol for hyperlipidemia therapy: An hypothesis

作者：Pan, Yanna; He, Shuai; Liao, Guoping; Chen, Lijing; Zhang, Zhongyi^*

来源：African Journal of Pharmacy and Pharmacology, 2012, 6(6): 355-358.

DOI：10.5897/AJPP11.768

• Hyperlipidemia
• gamma-oryzanol
• berberine

Hyperlipidemia has been thought to be a modifiable risk of coronary heart disease (CHD), and the patients generally require a chronic medication and a diet or lifestyle regulation to manage their hyperlipidemia. Meanwhile, the numbers of patients suffering from side effects are also increasing. Thus, development of novel, potent, safe and highly effective approaches to battle the world epidemics of hyperlipidemia is of crucial importance. It was reported that berberine and gamma-oryzanol could reduce total plasma cholesterol (TC) and triglyceride (TG) levels and increase the high density lipoprotein cholesterol (HDL-C) level both in vitro and in vivo. Therefore, a novel hypothesis concerning the combination of berberine and gamma-oryzanol for hyperlipidemia therapy is proposed. Moreover, if the poor bioavailability of berberine and gamma-oryzanol can be improved, the primary hypothesis will be reasonable and feasible, and also, serve as the basis for further improvement in quality of hyperlipidemia management.

• 出版日期2012-2
• 单位南方医科大学